Newsletter · 2026-07-06 · Ashutosh Agarwal

Medicare's Bridge Opens the Obesity Drug Floodgates for Lilly and Novo - The Obesity-Drug Pipeline - Week of July 6, 2026

The Obesity-Drug Pipeline newsletter for the week of July 6, 2026. Medicare's GLP-1 Bridge went live July 1 at a $50 copay on a $245 net price, retatrutide stretched the efficacy ceiling to 30% weight loss, and branded net price collapsed toward $150, pulling the volume story and the price story in opposite directions for Lilly, Novo and Hims.

The Obesity-Drug Pipeline

Week of July 6, 2026: Medicare's Bridge Opens the Obesity Drug Floodgates for Lilly and Novo

Issue #1 · July 6, 2026

For the first time in the program's history, Medicare is paying for weight-loss drugs. The "Bridge" pilot went live July 1, and it reframes the single biggest overhang on the incretin trade, the ~65-and-over population that federal law had walled off. Everything else this week (efficacy readouts, the price collapse, small-town budget pain) orbits that one fact.

TL;DR

• Medicare's GLP-1 "Bridge" launched July 1, letting eligible seniors get Wegovy, Zepbound and the new oral drugs for a $50/month copay on a net price of $245/month, and Leerink's David Reisinger pegs the eventual prize at ~$1B a year each for Lilly and Novo (Squawk on the Street).
• Retatrutide keeps stretching the efficacy ceiling, the TRIUMPH data revealed at ADA showed 30.3% weight loss (≈85 lbs) at 104 weeks and a 60% cut in the apnea-hypopnea index (DOC Updates).
• The branded price war is basically over, a Hims & Hers exec says consumer pressure dragged branded GLP-1s from $1,500 to $150/month, and Lilly and Novo have adopted the custom-dosing playbook (Prof G Markets).

What's New

1. Medicare's "Bridge" is now live, and it's a demonstration, not a mandate. On CNBC's Squawk on the Street (Jun 30), reporter Annika Kim Constantino (media/operator relay) called it "a watershed moment," noting eligible seniors pay a $50 monthly copay versus "several hundred dollars" cash. Leerink analyst David Reisinger (analyst/pundit) expects Medicare obesity coverage to "eventually rake in $1 billion in annual revenue for both Lilly and Novo." Two catches: it's temporary (expires Dec 31, 2027) and it runs outside Part D. The mechanics, laid out by the Weight and Healthcare newsletter (Jul 1, analyst/pundit): drugmakers charge the government a net $245/month, the beneficiary pays $50, and taxpayers cover the $195 balance. Eligibility is BMI ≥35 (no comorbidity needed) or BMI ≥27 with prediabetes, prior MI/stroke, HFpEF, uncontrolled hypertension or CKD stage 3a+.

2. The pill is the real battleground. Also on Squawk, Novo's own market research says 75% of seniors would prefer a pill over an injection, which matters now that the Wegovy oral launched early this year and Lilly's oral (orforglipron) launched in April. Storage, transport and titration all favor pills for the Medicare cohort. Watch this as the LLY-vs-NVO share fight of 2026-27.

3. Retatrutide is still the efficacy king; CagriSema underwhelms on the margin. On DOC Updates (Jun 30), ADA faculty Neil Skolnik and John Russell (clinical insiders) walked through fresh journal data. Lilly's retatrutide (the "triple-G" GIP/GLP-1/glucagon) hit A1C drops of 1.69–1.94% across 4–12 mg in the Phase 3 TRANSCEND T2D-1 trial, and the TRIUMPH obesity reveal showed 28% weight loss at 80 weeks (≈70 lbs) rising to 30.3% (≈85 lbs) at 104 weeks, plus a 60% reduction in apnea-hypopnea index, better than tirzepatide's OSA result. Novo's CagriSema (Reimagine-1, 189 T2D patients) posted a 1.8% A1C drop and ~14% weight loss at the 2.4mg dose, solid, but the hosts noted it's "roughly" what semaglutide monotherapy delivers, so the amylin add-on has something to prove.

4. The branded price collapse is a done deal. On Prof G Markets (Jul 5), a Hims & Hers executive (operator/insider) said the company compounded personalized GLP-1s for ~$150 (cost ~$80 all-in) against a $1,500 branded list price, and, with a push from TrumpRx, "those medications are now available to consumers for $150, the brand-name medications." He also flagged that 70-80% of patients stopped within 90 days from GI side effects, which pushed Lilly (LillyDirect vials, custom dosing, QuickPens) and Novo (Wegovy pill) toward titratable, personalized dosing. Hims now partners with Novo directly.

5. Someone has to pay, and towns are noticing. The Journal. (Jun 29) reported that GLP-1 scripts are "gobbling up small-town budgets," with one Massachusetts town (Duxbury) seeing ~7% of plan members on the drugs, a preview of the commercial-payer backlash that scales with penetration.

The Debate

Bull: Obesity is a 100-million-plus American addressable market barely into penetration, and the demand wall just got taller, Medicare access removes the last structural exclusion, the pill format widens the funnel, and next-gen molecules (retatrutide at 30%+ weight loss) keep resetting the efficacy bar in Lilly's and Novo's favor. Durable branded franchises, expanding into CVD, OSA, MASH and CKD.

Bear: The economics are getting squeezed from both ends. The Bridge is explicitly a two-year demonstration, and the Weight and Healthcare host cites a CBO projection of $35B in coverage cost (2026-2034) against just $3.4B in savings, exactly the math that gets a pilot killed rather than renewed. Net price has already cratered to $150 branded, real-world discontinuation runs 70-80% in 90 days, and skeptics like Dr. Ford Brewer (PrevMed, Jul 1, clinical insider/pundit) argue 40-60% of the weight lost is muscle, feeding a persistence problem.

Our read: The volume story is winning and the price story is losing, simultaneously. The question for the book isn't whether penetration compounds (it will) but whether net price per script holds anywhere near current levels once Medicare's $245 print becomes the reference point and every commercial payer benchmarks to it. Mix toward pills and toward comorbidity indications is where the defensible margin now lives.

Stocks in Play

Read-Throughs

• Fast-followers (AMGN MariTide, VKTX VK2735, Roche CT-388/CT-996): Silent this week, zero podcast mentions. With retatrutide printing 30%+, the bar for a fourth/fifth entrant just rose; the quiet is not comforting for the also-rans.
• Contract manufacturing / fill-finish (CTLT, LNZA, TMO): No coverage. The pivot toward oral pills (which don't need fill-finish or injector capacity) is a slow-burn negative for injectable-tied CDMO capacity theses, worth watching even when quiet.
• Pen / auto-injector suppliers (Ypsomed, Gerresheimer, Phillips Medisize): No coverage, same oral-shift risk. Silence here is data given how central pens were to the 2024-25 bull case.
• Insurers / PBMs (CVS/Caremark, CI/Express Scripts, UNH/Optum Rx): No direct commentary, but the Bridge's out-of-Part-D structure and the $245 net-price benchmark are the story they'll be reacting to next.
• Medtech / bariatric: One anecdote of a patient denied bariatric surgery then losing 90 lbs on GLP-1s, the substitution risk to bariatric volumes remains live but wasn't quantified.
• Food / QSR: No hard datapoints this week beyond the broad "GLP-1 economy reshaping consumption" framing.

What Changed vs Last Week

This is Issue #1 of The Obesity-Drug Pipeline, no prior issue to diff against. Baseline established: Medicare Bridge is the anchor event, retatrutide is the efficacy leader, branded net price has collapsed to ~$150, and the entire fast-follower/supply-chain complex (MariTide, VK2735, Roche, CDMOs, pen makers, state legislation like the Tennessee Fair Rx Act) was quiet, the yardstick for next week.